Top Markets
Coin of the day
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc.

USRM
Rank in Stocks #41992
U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and... U.S. Stem Cell, Inc. is a biotechnology firm dedicated to the advancement and commercialization of autologous cellular therapies throughout the United States. Its core mission is to address a range of medical conditions, including both chronic and acute forms of heart damage, along with various vascular and autoimmune disorders. Among its leading experimental treatments are MyoCell, a clinical-stage therapy designed to utilize a patient's own muscle cells to regenerate scar tissue within the heart, aiming to enhance cardiac function for individuals suffering from chronic heart failure. Another significant offering is AdipoCell, a cell therapy also derived from the patient's own body, developed to combat conditions such as acute myocardial infarction, persistent heart ischemia, and ischemia affecting the lower limbs. The company's developmental pipeline also features MyoCell SDF-1, another autologous cellular therapy derived from muscle, intended to boost cardiac performance in chronic heart failure patients. Furthermore, U.S. Stem Cell is actively developing MyoCath, an innovative deflecting-tip needle injection catheter specifically engineered to deliver therapeutic cells directly into heart tissue, addressing chronic heart ischemia and congestive heart failure. Beyond its product development, the company offers a suite of services, including training programs in regenerative medicine and cell therapy for both medical professionals and patients. It also facilitates cell collection and storage, provides specialized kits for cell collection and treatment for both human and veterinary applications, and manages its own cell therapy clinic. This clinic delivers cellular treatments for a broad spectrum of conditions, such as neurological, autoimmune, orthopedic, and degenerative disorders. Previously known as Bioheart, Inc., the company adopted its current name, U.S. Stem Cell, Inc., in October 2015. Established in 1999, its corporate headquarters are situated in Sunrise, Florida.
Share Price
$0.00001
Last synced: 2026-08-07
Market Cap
$6.42K
Change (1 day)
-90.00%
Change (1 year)
-90.00%
Country
US
Trade U.S. Stem Cell, Inc. (USRM)

Category

Price of USRM with the market cap of B
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
USRM
$0.00001
Market Capitalization of U.S. Stem Cell, Inc.(USRM)
Market Cap: $6.42K
As of August 2026 U.S. Stem Cell, Inc. has a market cap of $6.42K. This makes U.S. Stem Cell, Inc. the world's 41992nd most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of U.S. Stem Cell, Inc. from 2008 to 2026
USRM compared with Top 5 Most Popular stocks
Price of USRM Asset B Mkt. of B Results
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$8,391.83 $6.42K
$5.383T +83,918,307,928.06%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$6,895.39 $6.42K
$4.423T +68,953,876,809.40%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$6,485.38 $6.42K
$4.160T +64,853,770,735.26%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$5,710.55 $6.42K
$3.663T +57,105,546,852.46%
U.S. Stem Cell, Inc. U.S. Stem Cell, Inc.
$4,506.98 $6.42K
$2.891T +45,069,817,443.26%